MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
Status:
Completed
Trial end date:
2021-03-09
Target enrollment:
Participant gender:
Summary
This a Phase I, Open-Label, Multicentre Study to assess the safety, tolerability,
pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with
MEDI4736 (anti PD-L1) in Subjects with Non-small cell lung cancer (NSCLC). The study consists
of two phases: Escalation phase and an expansion phase to be conducted in locally advanced or
metastatic NSCLC subjects